<DOC>
	<DOCNO>NCT00290628</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy total-body irradiation donor umbilical cord blood transplant help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . When stem cell relate unrelated donor , exactly match patient 's blood , infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . PURPOSE : This clinical trial study well donor umbilical cord blood transplant work treat patient hematologic cancer .</brief_summary>
	<brief_title>Donor Umbilical Cord Blood Transplant Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine engraftment potential umbilical cord blood ( UCB ) patient hematological cancer . - Determine safety UCB transplantation patient . Secondary - Determine rate neutrophil platelet recovery completeness donor cell engraftment . - Determine incidence severity acute chronic graft-versus-host disease . - Determine incidence relapse patient malignant disease . - Determine probability survival event-free survival ( EFS ) 1 2 year UCB transplantation . OUTLINE : Patients stratify accord degree HLA disparity ( 0-1 v 2-3 disparity donor recipient ) , donor type ( related v unrelated ) , basis cell dose ( &lt; 2 v ≥ 2 x 10^7 nucleated cells/kg recipient body weight ) . Patients assign 1 4 treatment group accord disease* . NOTE : *Patients acute lymphocytic leukemia ( ALL ) , secondary acute myeloid leukemia ( AML ) , severe combine immunodeficiency , familial erythrophagocytic lymphohistiocytosis ( FEL ) /viral-associated hemophagocytic syndrome ( VAHS ) , inborn error metabolism , aplastic anemia , Fanconi 's anemia , Diamond-Blackfan anemia unrelated umbilical cord blood donor may proceed directly transplantation . - Preparative regimen : - Group 1 ( patient chronic myelogenous leukemia , AML , myelodysplastic syndrome , ALL ) : Patients receive cyclophosphamide IV daily day -7 -6 . Patients undergo total-body irradiation ( TBI ) twice daily day -4 -1 . Patients undergo unrelated allogeneic umbilical cord blood transplantation ( UCBT ) also receive methylprednisone IV anti-thymocyte globulin ( ATG ) IV twice daily day -2 -1 . - Group 2 ( patient infant leukemia ) : Patients receive busulfan orally IV four time daily day -9 -6 melphalan IV daily day -4 -2 . Patients undergo unrelated allogeneic UCBT also receive methylprednisolone IV ATG IV twice daily day -2 -1 . - Group 3 ( patient inborn error metabolism ) : Patients receive busulfan orally IV four time daily day -9 -6 cyclophosphamide IV daily day -5 -2 . Patients undergo unrelated allogeneic UCBT also receive methylprednisolone IV ATG IV twice daily day -2 -1 . - Group 4 ( patient aplastic anemia ) : Patients receive cyclophosphamide IV daily day -6 -3 ATG IV twice daily day -5 -3 . Patients undergo TBI day -2 . - Allogeneic UCBT : Patients undergo UCBT day 0 . Patients inborn error metabolism receive methylprednisolone IV UCBT day 0 . - Graft-versus-host disease ( GVHD ) prophylaxis : Patients receive 1 follow regimen : - Related donor UCBT : Patients receive cyclosporine IV 2 hour orally begin day -3 continue day 60 . - Unrelated donor UCBT myeloablative preparative regimen : Patients receive cyclosporine orally IV 2 hour twice daily begin day -3 continue day 180 . Patients also receive methylprednisolone IV twice daily day 5-19 . - Unrelated donor UCBT nonmyeloablative preparative regimen : Patients receive cyclosporine IV 2 hour orally twice daily begin day -3 continue day 180 . Patients also receive mycophenolate mofetil IV orally begin day 5 continue day 30 7 day active GVHD control . All patient receive filgrastim ( G-CSF ) IV begin day 1 continue blood count recover . Patients follow periodically 2 year . PROJECTED ACCRUAL : A total 60 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Fanconi Anemia</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Anemia , Diamond-Blackfan</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 following : Leukemia include , limited , follow subtypes : Chronic myelogenous leukemia Acute myeloid leukemia ( primary secondary ) Acute lymphoblastic leukemia Lymphoma Myelodysplastic syndrome Aplastic anemia Fanconi 's anemia DiamondBlackfan anemia Inborn error metabolism ( e.g. , Hurler syndrome , MaroteauxLamy syndrome , myelodysplastic syndrome VI , metachromatic leukodystrophy , adrenoleukodystrophy , globoid cell leukodystrophy ) Immune deficiency disorder Patients must meet eligibility requirement outline currently active treatment protocol University Minnesota Bone Marrow Transplant Program HLAidentical 1 , 2 , 3 antigen mismatch umbilical cord blood ( UCB ) donor least one DRB1 match available Unrelated relate donor UCB specimen must contain ≥ 2.0 x 10^7 nucleated cells/kg patient body weight PATIENT CHARACTERISTICS : See Disease Characteristics No active infection No history HIV infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>chronic eosinophilic leukemia</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic neutrophilic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>juvenile myelomonocytic leukemia</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>Diamond-Blackfan anemia</keyword>
	<keyword>Fanconi anemia</keyword>
	<keyword>childhood myelodysplastic syndrome</keyword>
</DOC>